During the first quarter, our focus has been on concluding the 510(k) process with the FDA. We had several meetings with the FDA and completed a SIR process (Submission Issue Request), which provided us with valuable feedback on how we should supplement our application with additional information.
Based on that, we were able to address all the areas where the FDA has requested additional information. We will be submitting that supplemental documentation at the beginning of September and, with normal processing time from the FDA, we should receive a response from them also during the month of September. The possible outcomes of that are, either approval (clearance), or a request to submit more information.
In preparation for our launch in the USA, we have grown the commercial part of the organization in both Sweden and the USA. Our latest recruitment is Warren Cresswell as President Americas. He has 25 years of experience in the diagnostics industry, bringing with him an extensive network and experience for building up and leading successful commercial organizations.
One of the most essential cornerstones of a successful commercialization of DiviTum®TKa in the USA is reimbursement from payers. Warren’s experience in this area is an important puzzle piece for this effort. With Warren at the helm in the USA, I am convinced that we will succeed with our launch and inclusion in the reimbursement system. Please read more about Warren’s background on page 3.
One of Biovica’s strengths is all of the positive results from clinical trials using the assay. At the ASCO annual meeting during 4-8 June 2021, results from a new study in a new area were presented. The study was carried out by Karolinska University Hospital and it is significant to us in that it serves as Proof of Concept in a new, important area. They show the prognostic and predictive capabilities of DiviTum®TKa for metastatic cutaneous melanoma patients undergoing immunotherapy. There is a large need in this area for better biomarkers, which is why the results are so promising, providing an additional strong indication that DiviTum®TKa has great potential beyond our first indication of metastatic breast cancer as well as immunotherapy.
Simultaneous with commercialization of DiviTum®TKa for metastatic breast cancer, Biovica will be working with additional regulatory approval for use of the assay with other indications than metastatic breast cancer, which is called intended use extension. Our belief is that, in the future, wide clinical use of DiviTum®TKa will be possible for a number of commonly occurring types of cancer.
At the company’s capital market day in May, we presented our plan for the areas where we intend to expand beyond that of breast cancer. The three areas we will first focus on are metastatic cancer in the areas of malignant melanoma, prostate cancer and lung cancer. These three areas more than double the already large market potential for our product.
We are looking forward to the upcoming commercialization and soon being able to make a meaningful difference for patients with metastatic breast cancer. We are excited and optimistic about the remainder of 2021 and all it holds.
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, firstname.lastname@example.org, +46 8 528 00 399. For more information please visit: www.biovica.com.
This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-08-31 08:00 CEST.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.